First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder

Abstract

Background:

3,4-methylenedioxymethamphetamine (MDMA) therapy has qualities that make it potentially well suited for patients with addictions, but this has never been explored in a research study. We present data from the Bristol Imperial MDMA in Alcoholism (BIMA) study. This is the first MDMA addiction study, an open-label safety and tolerability proof-of-concept study investigating the potential role for MDMA therapy in treating patients with alcohol use disorder (AUD).

Aims:

This study aimed to assess if MDMA-assisted psychotherapy can be delivered safely and can be tolerated by patients with AUD post detoxification. Outcomes regarding drinking behaviour, quality of life and psychosocial functioning were evaluated.

Methods:

Fourteen patients with AUD completed a community alcohol detoxification and received an eight-week course of recovery-based therapy. Participants received two sessions with MDMA (187.5 mg each session). Psychological support was provided before, during and after each session. Safety and tolerability were assessed alongside psychological and physiological outcome measures. Alcohol use behaviour, mental well-being and functioning data were collected for nine months after alcohol detoxification.

Results:

MDMA treatment was well tolerated by all participants. No unexpected adverse events were observed. Psychosocial functioning improved across the cohort. Regarding alcohol use, at nine months post detox, the average units of alcohol consumption by participants was 18.7 units per week compared to 130.6 units per week before the detox. This compares favourably to a previous observational study (the ‘Outcomes’ study) by the same team with a similar population of people with AUD.

Conclusions:

This study provides preliminary support for the safety and tolerability of a novel intervention for AUD post detox. Further trials to examine better the therapeutic potential of this approach are now indicated.

Keywords

MDMA alcohol use disorder psychotherapy alcoholism psychedelics

Get full access to this article

View all access options for this article.

References

American Psychiatric Association (APA) (2013) Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: APA.

Anton

O’Malley

Ciraulo

, et al. (2006) Combined pharmacotherapies and behavioural Interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA 293: 2003–2017.

Carhart-Harris

Murphy

Leech

, et al. (2014) The effects of acutely administered MDMA on spontaneous brain function in healthy volunteers measured with arterial spin labelling and BOLD resting-state functional connectivity. Biol Psychiatry 78: 554–562.

Carhart-Harris

Wall

Erritzoe

, et al. (2013) The effect of acutely administered MDMA on subjective and BOLD fMRI responses to favourite and worst autobiographical memories. Int J Neuropsychopharmacol 17: 527–540.

Castillo-Carniglia

Keyes

Hasin

, et al. (2019) Psychiatric comorbidities in alcohol use disorder. The Lancet Psychiatry, 6: 1068–1080.

Clay

Parker

(2020) Alcohol use and misuse during the COVID-19 pandemic: a potential public health crisis? Lancet Public Health 5: e259.

Greer

Tolbert

(1998) A method of conducting therapeutic sessions with MDMA. J Psychoactive Drugs 30: 371–379.

Hamer

Simpson

(2009) Last observation carried forward versus mixed models in the analysis of psychiatric clinical trials. Am J Psychiatry 166: 639–641.

Hanson

Luciana

(2010) Neurocognitive impairments in MDMA and other drug users: MDMA alone may not be a cognitive risk factor. J Clin Exp Neuropsychol 32: 337–349.

10.

Harris

Baggott

Mendelson

, et al. (2002) Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 162: 396–405.

11.

Jerome

Schuster

Berra Yazar-Klosinski

(2013) Can MDMA play a role in the treatment of substance abuse? Curr Drug Abuse Rev 6: 54–62.

12.

Krampe

Stawicki

Wagner

, et al. (2006) Follow-up of 180 alcoholic patients for up to 7 years after outpatient treatment: impact of alcohol deterrents on outcome. Alcohol Clin Exp Res 30: 86–95.

13.

Kuypers

Ramaekers

(2007) Acute dose of MDMA (75 mg) impairs spatial memory for location but leaves contextual processing of visuospatial information unaffected. Psychopharmacology 189: 557–563.

14.

Lingford-Hughes

Welch

Peters

, et al. (2012) BAP updated guidelines: evidence-based guidelines for the pharmacological management of substance abuse, harmful use, addiction and comorbidity: recommendations from BAP. J Psychopharmacol 26: 899–952.

15.

Marcus

Zgierska

(2009) Mindfulness-based therapies for substance use disorders: part 1 (Editorial). Subst Abus 30: 263.

16.

Miller

Wilbourne

(2002) Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 97: 265–277.

17.

Mithoefer

Feduccia

Jerome

, et al. (2019) MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six Phase 2 randomized controlled trials. Psychopharmacology 236: 2735–2745.

18.

Mithoefer

Wagner

Mithoefer

, et al. (2010) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25: 439–452.

19.

Mithoefer

Wagner

Mithoefer

, et al. (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependence after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow- up study. J Psychopharmacol 27: 28–39.

20.

NICE (2011) Alcohol-use Disorders: Diagnosis, Assessment and Management of Harmful Drinking and Alcohol Dependence. NICE clinical guideline 115. Available at: www.nice.org.uk/CG115 (accessed 1 June 2020).

21.

Paille

Martini

(2014) Nalmefene: a new approach to the treatment of alcohol dependence. Subst Abuse Rehabil 5: 87–94.

22.

Project MATCH Research Group (1998) Matching alcoholism treatments to client heterogeneity: Project MATCH three year drinking outcomes. Alcohol Clin Exp Res 22: 1300–1311.

23.

Rösner

Hackl-Herrwerth

Leucht

, et al. (2010) Acamprosate for alcohol dependence. Cochrane Database Syst Rev CD004332.

24.

Selvaraj

Hoshi

Bhagwagar

, et al. (2009) Brain serotonin transporter binding in former users of MDMA (‘ecstasy’). Br J Psychiatry 194: 355–359.

25.

Sessa

(2018) Why MDMA therapy for alcohol use disorder and why now? Neuropharmacology 142: 83–88.

26.

Sessa

Johnson

(2015) Is there a role for psychedelics in the treatment of drug dependency? Br J Psychiatry 206: 1–3.

27.

Sessa

Higbed

Nutt

(2019) A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Front Psychiatry 10: 138.

28.

Sessa

Higbed

O’Brien

, et al. (2020) How well are patients doing post-alcohol detox in Bristol? Results from the outcomes study. J Alcohol Drug Depend Subst Abuse 6: 021.

29.

Soyka

Rösner

(2008) Opioid antagonists for pharmacological treatment of alcohol dependence – a critical review. Curr Drug Abuse Rev 1: 280–291.

30.

Stolaroff

(2004) The Secret Chief Revealed: Conversations with a Pioneer of the Underground Therapy Movement. Sarasota: Multidisciplinary Association for Psychedelic Studies, pp.45–49.

31.

Sumnall

Cole

Jerome

(2006) The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy. J Psychopharmacol 20: 670–682.

32.

UK Alcohol Treatment Trial Research Team (2005) Effectiveness of treatment for alcohol problems: findings of the randomised UK Alcohol Treatment Trial (UKATT). BMJ 311: 541–544.